Patents Assigned to Institut National de la Sante et de la Recherche Medicale (Inserm)
  • ENZYMATIC BIOCATHODE, METHOD FOR PRODUCING IT AND FUEL BIOCELL AND BIOSENSOR COMPRISING THIS ENZYMATIC BIOCATHODE
    Publication number: 20220275420
    Abstract: A biomass-based enzymatic biocathode based on glucose, monosaccharide, ketone or aldehyde includes a collector conductor support, conductive particles disposed on and bound to said collector conductor support, and an aldose reductase disposed on said conductive particles, being bound thereto by adsorption and accessible at the surface of the monosaccharide, ketone or aldehyde reagent that is to be reduced when the biocathode is operational.
    Type: Application
    Filed: July 27, 2020
    Publication date: September 1, 2022
    Applicants: UNIVERSITÉ GRENOBLE ALPES, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MEDICALE - INSERM, GRENOBLE INP (INSTITUT NATIONAL POLYTECHNIQUE), CNRS - CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Abdelkader ZEBDA, Philippe CINQUIN, Donald MARTIN, Thomas SORANZO
  • Method for generating T cells progenitors
    Patent number: 11426430
    Abstract: The invention relates to an in vitro method to generate T cell progenitors, comprising the step of culturing CD34+ cells in a medium containing TNF-alpha and/or an antagonist of the Aryl hydro-carbon/Dioxin receptor, in particular StemRegenin 1 (SR1), in presence of a Notch ligand and optionally a fibronectin fragment.
    Type: Grant
    Filed: September 2, 2020
    Date of Patent: August 30, 2022
    Assignees: Assistance Publique—Hopitaux de Paris, Fondation Imagine—Institut des Maladies Génétiques, UniversitéParis Cite, Institut National de la Santé et de la Recherche Médicale (INSERM)
    Inventors: Isabelle André, Marina Cavazzana, Kuiying Ma, John Tchen, Tayebeh-Shabi Soheili, Ranjita Devi Moirangthem
  • Method for rejuvenating cells
    Patent number: 11414649
    Abstract: The invention relates to a method for reprogramming cells from aged donors or senescent cells to pluripotent cells that have lost marks of senescence. In particular, the invention relates to an ex vivo method for preparing induced pluripotent stem cells (iPSCs) from a target cell population comprising cells from aged donors or senescent cells, said method comprising the steps of culturing said target cell population under appropriate conditions for reprogramming said cells into iPSCs, wherein said appropriate conditions comprises increasing expression in said target cells, of at least the following reprogramming factors: Oct4, Klf4, Sox2, c-Myc, Lin28 and, optionally Nanog.
    Type: Grant
    Filed: December 5, 2019
    Date of Patent: August 16, 2022
    Assignees: INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE MONTPELLIER I, UNIVERSITE MONTPELLIER II
    Inventors: Alexandre Prieur, Ollivier Milhavet, Jean-Marc Lemaitre, Laure Lapasset
  • Selective organic cation transporters inhibitors for the treatment of depressive disorders
    Patent number: 11414398
    Abstract: Disclosed are organic cation transporters (OCTs) inhibitors of Formula (A), as well as their pharmaceutically acceptable tautomers, salts or solvates. Also disclosed are pharmaceutical compositions including such OCTs inhibitor of Formula (A) and their use for treating and/or preventing mood-related disorders such as depressive disorders.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: August 16, 2022
    Assignees: SORBONNE UNIVERSITÉ, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITÉ PARIS CITÉ
    Inventors: Sophie Gautron, Nicolas Pietrancosta, Francine Acher, Laetitia Chausset-Boissarie
  • Device for illuminating an object with a controlled light intensity and associated method
    Patent number: 11400311
    Abstract: The invention concerns a device 10 for illuminating an object 12 with a controlled light intensity, the light intensity being controlled when the light intensity fulfills a plurality of conditions to be fulfilled, the plurality of conditions comprising a condition relative to the intensity at a given time and a condition relative to the dose during a period of time.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: August 2, 2022
    Assignees: GENSIGHT BIOLOGICS, SORBONNE UNIVERSITÉ, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Joël Chavas, Guillaume Chenegros, Benjamin R. Benosman
  • Method for post-processing liver MRI images to obtain a reconstructed map of the internal magnetic susceptibility
    Patent number: 11403752
    Abstract: In the field of obesity related disease, identification of patients with nonalcoholic steatohepatitis (NASH) would be useful to counsel them more intensively on diet and lifestyle changes and propose new pharmacological treatments. As a consequence, the inventors worked on a method for post-processing images of a region of interest of the liver for reconstructing a map of the internal magnetic susceptibility by using a Bayesian regularization approach to inverse the internal magnetic field. Such method can be implemented on computer and provides better results than other known methods for obesity related disease. This method may be applied for predicting that a subject is at risk of suffering from such disease, diagnosing a disease, identifying a therapeutic or a biomarker and screening compounds useful as a medicine.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: August 2, 2022
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PARIS DIDEROT—PARIS 7, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, UNIVERSITE DE VERSAILLES SAINT-QUENTIN-EN-YVELINES
    Inventors: Benjamin Leporq, Simon Lambert, Bernard Van Beers
  • Ultrasonic method and device for characterising weak anisotropic media, and ultrasonic probe assembly for such a characterisation device
    Patent number: 11399804
    Abstract: A method for characterizing an anisotropic soft medium (C) including fibers and having an outer surface (1), by observing in different propagation directions, the propagation of a divergent shear wave from a central area (10) in the anisotropic soft medium. A propagation parameter of the shear wave is inferred therefrom in each of the propagation directions, and then a direction of the fibers of the anisotropic soft medium, a rheological elasticity parameter are determined in a direction perpendicular to the fibers and a rheological elasticity parameter in the direction of the fibers.
    Type: Grant
    Filed: January 12, 2015
    Date of Patent: August 2, 2022
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ECOLE SUPRERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS, UNIVERSITÉ PARIS DIDEROT—PARIS 7
    Inventors: Mickaël Tanter, Mathieu Pernot, Mathias Fink, Jean-Luc Gennisson
  • Benzoimidazole derivatives as anticancer agents
    Patent number: 11384081
    Abstract: The disclosure relates to benzoimidazole derivatives, acting as anticancer drugs, as well as pharmaceutical composition containing said compounds. These compounds are able to firstly inhibit the protein/protein interactions of the MAP Kinase Erk, leading to inhibition of proliferation and secondly to induce apoptosis in human cancer cell lines.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: July 12, 2022
    Assignees: CENTRE LEON BERARD, HOSPICES CIVILS DE LYON, UNIVERSITE CLAUDE BERNARD LYON 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Toufic Renno, Isabelle Coste-Invernizzi, Stéphane Giraud, Serge Lebecque
  • Dizocilpine derivatives as peripheral NMDA receptor antagonists
    Patent number: 11376245
    Abstract: The present invention relates to compounds of formula (I) for use as peripheral NMDA receptor antagonists.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: July 5, 2022
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE PARIS SUD, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS (APHP), HOPITAL MARIE LANNELONGUE
    Inventors: Sylvia Cohen-Kaminsky, Marc Humbert, Sebastien Dumas, Gilles Bru-Mercier, Samir Messaoudi, Jean-Daniel Brion, Mouad Alami, Gilles Galvani
  • CLOT RETRIEVAL DEVICES AND THERAPEUTIC USE THEREOF
    Publication number: 20220202429
    Abstract: The present invention relates to improved clot retrieval devices, wherein at least the part of the device intended to be in contact with a clot is coated with at least one chromatin binding agent selected from the group consisting of digoxigenin, a digoxigenin derivative, distamycin and a distamycin derivative. The present invention also relates to a method of producing said improved clot retrieval device. The present invention also relates to a method of prevention and/or treatment of stroke in a subject, comprising removing at least one clot using the clot retrieval device coated with said least one chromatin binding agent.
    Type: Application
    Filed: December 29, 2021
    Publication date: June 30, 2022
    Applicants: BALT EXTRUSION, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PARIS 13 - PARIS NORD, UNIVERSITE DE PARIS, FONDATION A DE ROTHSCHILD
    Inventors: Jean-Philippe Mickael DESILLES, Mikael MAZIGHI, Giuseppina CALIGIURI, Antonino NICOLETTI
  • Method for characterising bone using ultrasonic waves
    Patent number: 11369341
    Abstract: The invention relates to a method for characterising bone, the method comprising the steps of receiving (102) ultrasonic wave echo signals transmitted into a body, determining (104) a speed of sound in the body's non-bone biological tissue, locating (106) a first demarcation curve between non-bone biological tissue and bone in an image of the body constructed during said determining step, and determining (108) a speed of sound in bone. The steps of determining speed include constructing images from the signals, and a metric calculation indicative of a focus quality in the constructed images.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: June 28, 2022
    Assignees: SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS
    Inventors: Guillaume Renaud, Didier Cassereau
  • Hafnia alvei impact on regulation of appetite and metabolic syndrome aspects
    Patent number: 11369645
    Abstract: The present invention relates to method of preventing, treating or attenuating obesity-related manifestations in a human or non-human mammal subject in need thereof, said method comprising orally administering to the subject a composition comprising an effective amount Hafnia alvei probiotics; wherein said obesity-related parameters are selected from the group of hyperphagia, increased fat mass on lean mass ratio, increased waist circumference, postprandial hyperglycemia, fasting hyperglycemia and hypercholesterolemia.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: June 28, 2022
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE HOSPITALIER UNIVERSITAIRE DE ROUEN, UNIVERSITE DE ROUEN, TARGEDYS
    Inventors: Serguei Fetissov, Pierre Dechelotte, Jonathan Breton, Gregory Lambert, Nicolas Lucas, Romain Legrand
  • MONOCLONAL ANTIBODIES TO PROGASTRIN AND THEIR USES
    Publication number: 20220195035
    Abstract: The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.
    Type: Application
    Filed: March 7, 2022
    Publication date: June 23, 2022
    Applicants: Les Laboratoires Servier, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)
    Inventors: Julie Pannequin, Laure Boudier, Dominique Joubert, Frédéric Hollande
  • RAAV WITH CHEMICALLY MODIFIED CAPSID
    Publication number: 20220193252
    Abstract: The invention is directed to the field of gene therapy, i.e. gene delivery into target cells, tissue, organ and organism, and more particularly to gene delivery via viral vectors. The inventors showed that it is possible by chemical coupling to modulate the coupling of a ligand in the surface of the capsid of AAV, for example AAV2 and AAV3b. In particular, the present invention relates to a recombinant Adeno-Associated Virus (rAAV) vector particle having at least one primary amino group contained in the capsid proteins, chemically coupled with at least one ligand L wherein coupling of said ligand L is implemented through a bond comprising a —CSNH— bond and an optionally substituted aromatic moiety. Particularly, the inventors tested the chemical coupling of mannose ligand on AAV2 for subretinally injection to rats.
    Type: Application
    Filed: December 22, 2021
    Publication date: June 23, 2022
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE NANTES, CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES
    Inventors: Mathieu MEVEL, David DENIAUD, Eduard AYUSO
  • Ligand controling interaction between gags with their effector molecules and use thereof
    Patent number: 11357816
    Abstract: The invention relates to new compounds that mimic Glycosaminoglycans and are able to control interaction between Glycosaminoglycans with their effector molecules. The compounds of the invention are peptides and are able to prevent or reduce the binding of at least one effector molecule with at least one glycosaminoglycan. The compounds according to the invention can be used as drug, in particular for the stimulation of the neurogenesis and more generally to treat nervous system related pathologies.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: June 14, 2022
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), SORBONNE UNIVERSITE, ECOLE NORMALE SUPERIEURE, COLLEGE DE FRANCE
    Inventors: Jean-Maurice Mallet, Solange Lavielle, Rodrigue Marquant, Alain Prochiantz, Ariel Di Nardo, Damien Testa
  • Antagonist of the fibroblast growth factor receptor 3 (FGFR3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of FGFR3
    Patent number: 11357778
    Abstract: The present invention relates to the treatment or prevention of skeletal disorders, at particular skeletal diseases, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a constitutively activated mutant of FGFR3.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: June 14, 2022
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITÉ PARIS CITÉ, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, IMAGINE
    Inventors: Laurence Legeai-Mallet, Arnold Munnich, Patricia Busca, Florent Barbault
  • Prevention or treatment of hematologic malignancy relapse using a TNFR2 antagonist
    Patent number: 11359027
    Abstract: The present disclosure relates to the in vivo prevention or treatment of hematologic malignancy relapse using a TNFR2 antagonist (an anti TNFR2 antagonist antibody) (i) for use in the prevention or treatment of hematologic malignancy relapse after allogeneic hematopoietic stem cell transplantation (AHCT) or after a treatment with lymphocytes and (ii) for use in enhancing the graft-versus-leukemia-activity (GVL activity) of a hematopoietic stem cell transplantation (HCT) or a treatment with lymphocytes.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: June 14, 2022
    Assignees: UNIVERSITE PARIS EST CRETEIL VAL DE MARNE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Sébastien Maury, José Cohen, Benoît Salomon, Sina Naserian, Mathieu Leclerc
  • ANTIBODIES AGAINST TRIM9 AND/OR TRIM67 IN PARANEOPLASTIC NEUROLOGICAL SYNDROMES
    Publication number: 20220178949
    Abstract: The invention relates to a process in vitro for diagnosing a paraneoplastic neurological syndrome (PNS) associated with a tumor in an individual, comprising the detection of at least one antibody chosen among antibodies against TRIM9 and antibodies against TRIM67, in a biological fluid of said individual.
    Type: Application
    Filed: May 2, 2019
    Publication date: June 9, 2022
    Applicants: HOSPICES CIVILS DE LYON, UNIVERSITE CLAUDE BERNARD LYON 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Le Duy DO, Jérôme HONNORAT, Véronique ROGEMOND
  • Antiviral compositions for treating the flu
    Patent number: 11351180
    Abstract: The present invention relates to a pharmaceutical or veterinary composition for the use thereof in preventing and/or treating infection by the influenza viruses. Said composition is characterized in that it contains, in an appropriate pharmaceutical carrier, at least one compound selected from among Etilefrine and Diltiazem.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: June 7, 2022
    Assignees: UNIVERSITE CLAUDE BERNARD LYON 1, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), HOSPICES CIVILS DE LYON, UNIVERSITE LAVAL
    Inventors: Manuel Rosa-Calatrava, Olivier Terrier, Julien Textoris, Guy Boivin, Mario Pizzorno
  • Objective, camera and system adapted for optogenetics comprising such objective
    Patent number: 11320649
    Abstract: The present invention concerns an objective (10) for imaging an object field of view of 10° onto an imager (12), the objective (10) comprising in order of the propagating direction: —a first lens unit (U1) comprising several lenses, the first lens unit (U1) having a positive first focal length and a first dimension inferior to 15 millimeters, —a bending mirror (M) adapted to bend at a 90° angle, —a liquid lens (LL), and —a second lens unit (U2) comprising several lenses, the second lens unit (U2) having a positive second focal length and a second dimension, the ratio between the first focal length and the second focal length being comprised between 1.0 and 2.0 and the ratio between the first dimension and the second dimension being superior or equal to 2.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: May 3, 2022
    Assignees: GENSIGHT BIOLOGICS, Sorbonne Université, Centre National de la Recherche Scientifique, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Joël Chavas, Guillaume Chenegros, Charlie Galle